Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19
COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure. COVID-19 has led to more than 6.5 million deaths worldwide. The significant morbidity and mortali...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-04-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X231168304 |
| _version_ | 1797843595355488256 |
|---|---|
| author | Elizabeth DeMarco Matthew Turnipseed Brian Clarke Farhan Qadeer |
| author_facet | Elizabeth DeMarco Matthew Turnipseed Brian Clarke Farhan Qadeer |
| author_sort | Elizabeth DeMarco |
| collection | DOAJ |
| description | COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure. COVID-19 has led to more than 6.5 million deaths worldwide. The significant morbidity and mortality due to COVID-19 have resulted in the development of treatment modalities, such as novel antivirals, to reduce hospitalizations and progression of disease. In 2021, the US Food and Drug Administration authorized nirmatrelvir/ritonavir for emergency use in nonhospitalized patients with COVID-19. Nirmatrelvir is a newly developed protease inhibitor and is combined with a commonly used pharmacokinetic boosting agent, ritonavir. Given the novelty of nirmatrelvir/ritonavir, potential adverse effects remain uncertain. In this case, we describe a patient who was initiated on a course of nirmatrelvir/ritonavir and developed symptomatic bradycardia. |
| first_indexed | 2024-04-09T17:07:54Z |
| format | Article |
| id | doaj.art-ba4f6827c68d463487a927e5e666d4db |
| institution | Directory Open Access Journal |
| issn | 2050-313X |
| language | English |
| last_indexed | 2024-04-09T17:07:54Z |
| publishDate | 2023-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj.art-ba4f6827c68d463487a927e5e666d4db2023-04-20T11:04:36ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2023-04-011110.1177/2050313X231168304Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19Elizabeth DeMarcoMatthew TurnipseedBrian ClarkeFarhan QadeerCOVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure. COVID-19 has led to more than 6.5 million deaths worldwide. The significant morbidity and mortality due to COVID-19 have resulted in the development of treatment modalities, such as novel antivirals, to reduce hospitalizations and progression of disease. In 2021, the US Food and Drug Administration authorized nirmatrelvir/ritonavir for emergency use in nonhospitalized patients with COVID-19. Nirmatrelvir is a newly developed protease inhibitor and is combined with a commonly used pharmacokinetic boosting agent, ritonavir. Given the novelty of nirmatrelvir/ritonavir, potential adverse effects remain uncertain. In this case, we describe a patient who was initiated on a course of nirmatrelvir/ritonavir and developed symptomatic bradycardia.https://doi.org/10.1177/2050313X231168304 |
| spellingShingle | Elizabeth DeMarco Matthew Turnipseed Brian Clarke Farhan Qadeer Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19 SAGE Open Medical Case Reports |
| title | Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19 |
| title_full | Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19 |
| title_fullStr | Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19 |
| title_full_unstemmed | Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19 |
| title_short | Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19 |
| title_sort | possible nirmatrelvir ritonavir induced bradycardia in a patient with asymptomatic covid 19 |
| url | https://doi.org/10.1177/2050313X231168304 |
| work_keys_str_mv | AT elizabethdemarco possiblenirmatrelvirritonavirinducedbradycardiainapatientwithasymptomaticcovid19 AT matthewturnipseed possiblenirmatrelvirritonavirinducedbradycardiainapatientwithasymptomaticcovid19 AT brianclarke possiblenirmatrelvirritonavirinducedbradycardiainapatientwithasymptomaticcovid19 AT farhanqadeer possiblenirmatrelvirritonavirinducedbradycardiainapatientwithasymptomaticcovid19 |